natgillin/translations-raw huggingface dataset:
The rubber stopper of the vial may be safely punctured up to 20 times. 
Gumijasti zamašek viale lahko varno prebodete do 20-krat.
Generally, cross-resistance between tildipirosin and other macrolides, lincosamides or streptogramins is to be expected. 
Na splošno se pričakuje navzkrižna rezistenca med tildipirozinom in drugimi makrolidi, linkozamidi ali streptogramini.
The active substance in Zuprevo is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010: 
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL) Zdravilna učinkovina v zdravilu Zuprevo je dovoljena učinkovina, kot je navedeno v tabeli 1 (dovoljene snovi) priloge Uredbe Komisije (EU) št. 37/2010:
In very rare cases, anaphylactic reactions, with a potentially fatal outcome, might occur. 
V zelo redkih primerih se lahko pojavi anafilaktična reakcija z možnim poginom.
In very rare cases, transient lethargy in piglets has been observed. 
V zelo redkih primerih so pri pujskih opazili prehodno letargijo.
It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 48 hours after injection. 
Priporočljivo je zdraviti živali v zgodnjih fazah bolezni in ovrednotiti reagiranje na zdravljenje v 48 urah po injekciji.
In target animal safety studies, administration of the maximum recommended injection volume (5 ml) very commonly caused slight swellings at the injection site that were not painful on palpation. 
V varnostnih študijah na ciljnih živalskih vrstah je dajanje maksimalnega priporočenega odmerka (5 ml) zelo pogosto na mestu injiciranja povzročilo rahle otekline, ki niso bile boleče na otip.
The mean total excretion of the total dose administered within 14 days was about 17% in urine and 57% in faeces. 
Srednje celokupno izločanje celotnega odmerka, danega v 14 dneh, je bilo okrog 17 % z urinom in 57 % s fecesom.
Not for use in animals from which milk is produced for human consumption. 
Ni za uporabo pri živalih, katerih mleko se uporablja za prehrano ljudi.
Shelf life of the veterinary medicinal product as packaged for sale: 2 years. 
Rok uporabnosti zdravila za uporabo v pakiranju za prodajo: 2 leti
Do not use after the expiry date which is stated on the vial after EXP. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na viali za EXP.
It is recommended to treat animals in the early stages of the disease and to evaluate the response to treatment within 2 to 3 days after injection. 
Priporočljivo je zdraviti živali v zgodnjih stopnjah bolezni in ovrednotiti reagiranje na zdravljenje v 2 do 3 dneh po injekciji.
If accidental eye exposure occurs, flush eyes immediately with clean water. 
Če pride zdravilo v stik z očmi, oči takoj sperite s čisto vodo.
In vitro binding of tildipirosin to porcine plasma proteins is limited with approximately 30 %. 
In vitro vezava tildipirozina na beljakovine v prašičji plazmi je omejena na približno 30 %.
The mean total excretion of the total dose administered within 14 days was about 24% in urine and 40% in faeces. 
Srednje celokupno izločanje celotnega odmerka, danega v 14 dneh, je bilo okrog 24 % z urinom in 40 % s fecesom.
Tildipirosin is a 16-membered semi-synthetic macrolide antimicrobial agent. 
Tildipirozin je 16-členski polsintitetični makrolid z antimikrobnim delovanjem.
There is cross resistance with other macrolides. 
Obstaja navzkrižna odpornost z drugimi makrolidi.
Marketing authorisation holder: Intervet International B. V. 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM Intervet International B. V.
MANUFACTURER'S BATCH NUMBER Batch: 
IZDELOVALČEVA ŠTEVILKA SERIJE Serija:
Range (µg/ml) MIC50 (µg/ml) MIC90 (µg/ml) 
Razpon(µg/ml) MIK50 (µg/ml) MIK90 (µg/ml)
Administer strictly intramuscularly. 
Dajajte strogo intramuskularno.
Subcutaneous use. 
Subkutana uporaba
Tildipirosin may cause sensitisation by skin contact. 
Tildipirozin pri stiku s kožo lahko povzroči sensibilizacijo.
Another animal developed treatment related shock after the first administration and was euthanised on welfare grounds. 
Pri drugi živali se je po prvi injekciji pokazal z zdravljenjem povezan šok in so jo evtanazirali zaradi dobrobiti živali.
Following the maximum recommended injection site volume of 5 ml, injection site reactions resolved completely within 21 days. 
Po dajanju maksimalnega priporočenega odmerka 5 ml so reakcije na mestu injiciranja popolnoma izginile v 21 dneh.
Intervet International GmbH Feldstrasse 1 a 85716 Unterschleissheim GERMANY 
Feldstrasse 1 a 85716 Unterschleissheim NEMČIJA
If clinical signs of respiratory disease persist or increase, treatment should be changed using another antibiotic, and continued until clinical signs have resolved. 
Če se klinični znaki respiratorne bolezni še nadaljujejo ali povečajo, je treba zdravljenje spremeniti in uporabiti drug antibiotik in zdravljenje nadaljevati, dokler klinični znaki ne izginejo.
Do not use in case of hypersensitivity to macrolide antibiotics or to any of the excipients. 
Ne uporabite v primeru preobčutljivosti za makrolidne antibiotike ali za katero koli pomožno snov.
Pain on injection and injection site swellings are very common in treated animals. 
Bolečina ob injiciranju in otekline na mestu injiciranja so pri zdravljenih živalih zelo pogoste.
Special caution should be taken to avoid accidental self-injection, as toxicology studies in laboratory animals showed cardiovascular effects after intramuscular administration of tildipirosin. 
Posebno je treba paziti, da ne pride do nenamernega samoinjiciranja, saj so toksikološke študije na laboratorijskih živalih pokazale kardiovaskularne učinke po intramuskularnem dajanju tildipirozina.
For E. coli, Campylobacter and Enterococci, both wild type and non-wild type phenotypes were observed (MIC range 1-> 64 µg/ml). 
Za E. coli, Campylobacter in Enterococci,so bili ugotovljeni divji in nedivji fenotipi (razpon MIK 1.>64 µg/ml).
Following the maximum recommended injection site volume of 10 ml, injection site swellings may be associated with pain on palpation for about one day in individual animals. 
Po injiciranju maksimalnega priporočenega odmerka 10 ml je oteklina na mestu injiciranja pri posameznih živalih kakšen dan lahko povezana z bolečino na otip.
Do not use in case of hypersensitivity to macrolide antibiotics, citric acid monohydrate or propylene glycol. 
Ne uporabite zdravila v primeru preobčutljivosti za makrolidne antibiotike, citronsko kislinomonohidrat ali propilen glikol.
If clinical signs of respiratory disease persist or increase, or if relapse occurs, treatment should be changed using another antibiotic, and continued until clinical signs have resolved. 
Če se klinični znaki respiratorne bolezni še nadaljujejo ali povečajo, ali če se bolezen ponovi, je treba zdravljenje spremeniti in uporabiti drug antibiotik in zdravljenje nadaljevati, dokler klinični znaki ne izginejo.
The presence of the disease in the herd should be confirmed before preventive treatment. 
Pred preventivnim zdravljenjem je treba potrditi prisotnost bolezni v čredi.
Once opened, use within 28 days. 
Načeto zdravilo uporabite v 28 dneh.
Needle length (cm) 
Dolžina igle (cm)
Administer 4 mg tildipirosin/kg body weight (equivalent to 1 ml/45 kg body weight) once only. 
Dajte 4 mg tildipirozina/kg telesne teže (kar ustreza 1ml/45 kg telesne teže) samo enkrat.
Vial (100 ml, 250 ml) 
Viala (100 ml, 250 ml)
Box 
Škatla
Resistance to macrolides generally results from three mechanisms: (1) the alteration of the ribosomal target site (methylation), often referred to as MLSB resistance as it affects macrolides, lincosamides and group B streptogramins; (2) the utilisation of active efflux mechanism; (3) the production of inactivating enzymes. 
Rezistenca na makrolide je na splošno posledica treh mehanizmov: (1) spremembe ribosomskega ciljnega mesta (metilacija), ki jo pogosto označujejo kot rezistenco na MLSB, ker deluje na makrolide, linkozamide in na skupino B streptograminov, (2) izkoriščanja aktivnega mehanizma iztekanja; (3) proizvodnje inaktivirajočih encimov.
In vitro binding of tildipirosin to bovine plasma and bronchial fluid proteins is limited with approximately 30%. 
In vitro vezava tildipirozina na beljakovine v goveji plazmi in bronhialni tekočini je omejena na približno 30 %.
The efficacy of metaphylactic use of Zuprevo was demonstrated in a placebo controlled multi-centre field study, when outbreak of clinical disease was confirmed (i.e. animals in at least 30% of the pens sharing the same airspace showed clinical signs of SRD, including at least 10% animals per pen within 1 day; or 20% within 2 days or 30% within 3 days). 
Učinkovitost metafilaktične uporabe zdravila Zuprevo je bile dokazana v multicenrični s placebom kontrolirani terenski študiji, ko je bil potrjen izbruh klinične bolezni (tj., najmanj 30 % živali v enem boksu v istem prostoru je imelo klinične znake SRD, vključujoč najmanj 10 % živali v 1 dnevu ali 20 % živali v 2 dnevih ali 30 % živali v 3 dnevih).
If accidental skin exposure occurs, wash the skin immediately with soap and water. 
V primeru nenamernega razlitja po koži kožo takoj operite z milom in vodo.
The swellings are transient and will usually resolve within 7 to 16 days; in individual animals swellings may persist for 21 days. 
Otekline so prehodne in navadno splahnijo v 7 do 16 dneh.
During clinical trials, pain on injection and injection site swellings were seen very commonly in treated pigs. 
Med kliničnimi poskusi so bolečino ob injiciranju in otekline na mestu injiciranja na zdravljenih prašičih opazili zelo pogosto.
Administer 4 mg tildipirosin/kg body weight (equivalent to 1 ml/10 kg body weight) once only. 
Dajte 4 mg tildipirozina/kg telesne teže (kar ustreza 1ml/10 kg telesne teže) samo enkrat.
Metaphylaxis implies that clinically healthy animals in close contact with diseased animals are administered the product at the same time as the treatment of the clinically diseased animals, to reduce the risk for development of clinical signs. 
Pri metafilaksi je potrebno, da klinično zdrave živali, ki so v tesnem stiku z obolelimi živalmi, dobijo zdravilo istočasno kot obolele živali, da se zmanjša tveganje razvoja kliničnih znakov.
Intramuscular use. 
Intramuskularna uporaba
Metaphylaxis implies that clinically healthy animals in close contact with diseased animals are administered the veterinary medicinal product at the same time as the treatment of the clinically diseased animals, to reduce the risk for development of clinical signs. 
Pri metafilaksi je potrebno, da klinično zdrave živali, ki so v tesnem stiku z obolelimi živalmi, dobijo zdravilo za uporabo v veterinarski medicini istočasno kot obolele živali, da se zmanjša tveganje razvoja kliničnih znakov.
In cattle, it is postulated that metabolism of tildipirosin proceeds by cleavage of the mycaminose sugar moiety, by reduction and sulphate conjugation with subsequent hydration (or ring opening), by demethylation, by mono- or dihydroxylation with subsequent dehydration and by S-cysteine and Sglutathione conjugation. 
Pri govedu se predpostavlja, da metabolizem tildipirozina poteka z odcepitvijo micaminose dela sladkorja, z zmanjševanjem in konjugacijo sulfata z naknadno hidraciji (ali odprtjem obroča), z demetilacijo, z mono- ali dihidroksilacijo s posledično dehidracijo in s konjugacijo S-cisteina in Sglutationa.
Pathomorphological injection site reactions resolved completely within 21 days. 
Patomorfološke reakcije na mestu injiciranja so popolnoma izginile v 21 dneh.
In pigs, it is postulated that the metabolism of tildipirosin proceeds by reduction and sulphate conjugation with subsequent hydration (or ring opening), by demethylation, by dihydroxylation and by S-cysteine and S-glutathione conjugation. 
Pri prašičih se predpostavlja, da metabolizem tildipirozina poteka z redukcijo in konjugacijo sulfata z naknadno hidracijo (ali odprtjem obroča), z demetilacijo, s hidroksilacijo in s konjugacijo S-cisteina in S-glutationa.
To ensure correct dosage, body weight should be determined as accurately as possible to avoid underdosing. 
Da bi zagotovili pravilno odmerjanje, je treba čim natančneje določiti telesno težo, da ne bi bil odmerek premajhen.
40 mg. For the full list of excipients, see section 6.1. 
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
Resistance to macrolides generally results from three mechanisms: (1) the alteration of the ribosomal target site (methylation), often referred to as MLSB resistance as it affects macrolides, lincosamides and group B streptogramins, (2) the utilisation of active efflux mechanism; (3) the production of inactivating enzymes. 
Rezistenca na makrolide je na splošno posledica treh mehanizmov: (1) spremembe ribosomskega ciljnega mesta (metilacija), ki jo pogosto označujejo kot rezistenco na MLSB, ker deluje na makrolide, linkozamide in na skupino B streptograminov, (2) izkoriščanje aktivnega mehanizma iztekanja; (3)
To ensure correct dose, body weight should be determined as accurately as possible to avoid underdosing. 
Da bi zagotovili pravilen odmerek, je treba čim natančneje določiti telesno težo, da ne bi bil odmerek premajhen.
METHOD AND ROUTE OF ADMINISTRATION Subcutaneous injection 
NAČIN IN POT(I) UPORABE Subkutana injekcija
Therefore, the product should not be administered with antimicrobials with a similar mode of action such as other macrolides or lincosamides. 
Zato zdravila ne dajajte skupaj z antimikrobnimi zdravili s podobnim načinom delovanja, kot so drugi makrolidi ali linkozamidi.
Injection site reactions will largely resolve within 35 days. 
Reakcije na mestu injiciranja v glavnem izginejo v 35 dneh.
In vitro, the effect of tildipirosin is bactericidal against M. haemolytica and H. somni, and bacteriostatic against P. multocida. 
In vitro je delovanje tildipirozina bakteriocidno za M. haemolytica in H. somni, bakteriostatično pa za P. multocida.
Needle diameter (mm) 
Premer igle (mm)
Tildipirosin Bovine 400 μg/kg 
Tildipirozin Tildipirozin Govedo 400
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. 
Varnost zdravila za uporabo v veterinarski medicini ni bila ugotovljena v obdobju brejosti in laktacije.
Tildipirosin administered subcutaneously to cattle at a single dose of 4 mg/kg body weight resulted in rapid absorption with average peak plasma concentration of 0.7 µg/ml within 23 minutes (Tmax) and high absolute bioavailability (78.9%). 
Tildipirozin, ki so ga dajali subkutano govedom v enkratnem odmerku 4 mg/kg telesne teže, se je hitro absorbiral in dosegel največjo koncentracijo v plazmi 0.7 µg/ml v 23 minutah (Tmax) in visoko absolutno biorazpožljivost (78,9%).
Mannheimia haemolytica, Pasteurella multocida and Histophilus somni, the bacterial pathogens most commonly associated with bovine respiratory disease (BRD). 
Mannheimia haemolytica, Pasteurella multocida in Histophilus somni, bakterijske patogene, ki so najpogosteje povezani z respiratorno boleznijo goveda (BRD).
The safety of the veterinary medicinal product has not been established during pregnancy or lactation. 
Varnost zdravila za uporabo v veterinarski medicini v obdobju brejosti ali laktacije ni bila ugotovljena.
Tildipirosin administered intramuscularly to pigs at a single dose of 4 mg/kg body weight was rapidly absorbed reaching average peak plasma concentration of 0.9 µg/ml within 23 minutes (Tmax). 
Tildipirozin, ki so ga dajali prašičem intramuskularno v enkratnem odmerku 4 mg/kg telesne teže, se je hitro absorbiral in dosegel največjo koncentracijo v plazmi 0.9 µg/ml v 23 minutah (Tmax).
Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis, which are the bacterial pathogens most commonly associated with swine respiratory disease (SRD). 
Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica in Haemophilus parasuis, ki so bakterijski patogeni, najpogosteje povezani s prašičjo respiratorno boleznijo (SRD).
DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED Detailed information on this product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila
MARKETING AUTHORISATION NUMBERS EU/2/11/124/005-008 
ŠTEVILKA DOVOLJENJA ZA PROMET EU/2/11/124/005-008
Overdoses of 10 times the recommended dose as well as repeated subcutaneous administration of the veterinary medicinal product only led to transient clinical signs attributed to injection site discomfort and injection site swellings associated with pain in calves. 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) Preveliki odmerki 10-kratnega priporočenega odmerka kakor tudi ponovno subkutano dajanje zdravila za uporabo v veterinarski medicine je imelo za posledico le pri nekaterih živalih prehodne klinične znake neugodja in otekline na mestu injiciranja, povezane z bolečino pri teletih.
To be supplied only on veterinary prescription. 
Samo za živali - na veterinarski recept
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT(S) The veterinary medicinal product is a clear yellowish solution for injection containing 40 mg/ml of tildipirosin 
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGEIH SESTAVIN Zdravilo za uporabo v veterinarski medicini je bistra rumenkasta raztopina za injiciranje, ki vsebuje 40 mg/ml tildipirozina.
Do not administer simultaneously with other macrolides or lincosamides (see section 4.8) 
Ne dajajte istočasno z drugimi makrolidi ali linkozamidi (glejte poglavje 4.8)
STATEMENT OF THE ACTIVE SUBSTANCE AND OTHER INGREDIENT(S) ZUPREVO is a clear yellowish solution for injection containing 180 mg/ml of tildipirosin 
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGIH SESTAVIN ZUPREVO je bistra rumenkasta raztopina za injiciranje, ki vsebuje 180 mg/ml tildipirozina.
Cattle (meat and offal): 47 days. 
Govedo (meso in organi): 47 dni
PHARMACOLOGICAL PROPERTIES Pharmacotherapeutic group: antibacterials for systemic use, macrolides. 
FARMAKOLOŠKE LASTNOSTI Farmakoterapevtska skupina: : zdravila za sistemsko zdravljenje bakterijskih infekcij, makrolidni antiobiotiki
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Evropske agencije za zdravila (European Medicines Agency,http://www.ema.europa.eu/.
In calves, a single subcutaneous injection of 10 times the recommended dose (40 mg/kg body weight) and repeated subcutaneous administration of tildipirosin (on three occasions in intervals of 7 days) at 4, 12 and 20 mg/kg (1, 3 and 5 times the recommended clinical dose) were well tolerated, apart from transient clinical signs attributed to injection site discomfort and injection site swellings associated with pain in some animals. 
Teleta so dobro prenašala enkratni subkutani odmerek, ki je bil 10-krat večji od priporočenega odmerka (40mg/kg telesne teže) in ponovno subkutano dajanje tildipirozina (trikrat v razmikih po 7 dni) v odmerkih 4, 12 in 20 mg/kg (1-krat, 3-krat in 5-krat priporočeni klinični odmerek), le pri nekaterih živalih so opazili prehodne klinične znake neugodja in otekline na mestu injiciranja, povezane z bolečino.
At 20 mg/kg body weight one out of eight animals showed transient generalized body tremors with inability to stand after the first administration and the animal showed transient unsteadiness on its feet after the third administration. 
V skupini, ki je dobivala po 20 mg/kg telesne teže, se je pri eni živali od osmih po prvem odmerku pokazal prehoden generaliziran tremor in ni mogla stati, po tretjem odmerku pa so pri njej opazili prehodno nestabilnost.
The following tildipirosin breakpoints have been established for bovine respiratory disease (according to CLSI Guideline VET02 A3): 
Za govejo respiratorno bolezen (v skladu smernico CLSI VET02 A3) so določene naslednje predlagane preliminarne prelomne točke za tildipirozin:
Pathomorphological injection site reactions will largely resolve within 35 days. 
Patomorfološke reakcije na mestu injiciranja v glavnem izginejo v 35 dneh.
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROSTITEV SERIJE
Name and address of the manufacturer responsible for batch release 
Ime in naslov izdelovalca (izdelovalcev) zdravila, odgovornega (odgovornih) za sprostitev serije
The following tildipirosin breakpoints have been established for swine respiratory disease (according to CLSI Guideline VET02 A3): 
Za prašičjo respiratorno bolezen (v skladu s smernico CLSI VET02 A3) so določene naslednje predlagane preliminarne prelomne točke za tildipirozin:
Meat and offal: 47 days 
Meso in organi: 47 dni
Pharmacotherapeutic group: antibacterials for systemic use, macrolides. 
Farmakoterapevtska skupina: zdravila za sistemsko zdravljenje bakterijskih infekcij,makrolidni antiobiotiki
STATEMENT OF ACTIVE AND OTHER SUBSTANCES 180 mg/ml of tildipirosin 
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGIH SNOVI 180 mg/ml tildipirozina
Do not administer simultaneously with other macrolides or lincosamides (see section 12) 
Ne dajajte istočasno z drugimi makrolidi ali linkozamidi (glejte poglavje 12)
Do not administer simultaneously with other macrolides or lincosamides (see section 12). 
Ne dajajte istočasno z drugimi makrolidi ali linkozamidi (glejte poglavje 12).
Citric acid monohydrate Propylene glycol Water for injections 
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi Citronska kislina, monohidrat propilen glikol voda za injekcije
Muscle tremors to the hind legs were observed following the first treatment in one pig each from the 12 and 20 mg/kg bodyweight group. 
Mišični tremor v zadnjih nogah so opazili po prvem dajanju pri enem pujsku v skupinah, ki sta dobivali po 12 in 20 mg/kg telesne teže
Meat and offal: 9 days 
Meso in organi: 9 dni
For the treatment and prevention of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni sensitive to tildipirosin. 
INDIKACIJE Za zdravljenje in preprečevanje respiratorne bolezni goveda (BRD), povzročene z Mannheimia haemolytica, Pasteurella multocida in Histophilus somni, ki so občutljivi za tildipirozin.
Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis sensitive to tildipirosin. 
INDIKACIJE Zdravljenje in metafilaksa prašičje respiratorne bolezni (SRD), povzročene z Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica in Haemophilus parasuis, ki so občutljivi za tildipirozin.
Accumulation at the site of respiratory tract infection is demonstrated by high and sustained tildipirosin concentrations in lung and bronchial fluid, which far exceed those in blood plasma. 
Akumulacija na mestu infekcije respiratornega trakta, ki močno presega koncentracije v krvni plazmi,
Type I amber glass vial with a chlorobutyl rubber stopper and an aluminium cap. 
Viala iz rjavega stekla tipa I z zamaškom iz klorbutilne gume in aluminijasto zaporko
Disease Species 
Vrsta bolezni
Recommended needle size and diameter per production stage 
Priporočena velikost in premer igle glede na kategorija
In piglets, intramuscular administration of tildipirosin (on three occasions in intervals of 4 days) at 8, 12 and 20 mg/kg body weight (BW) (2, 3 and 5 times the recommended clinical dose), resulted in transient slightly subdued behaviour in one piglet each from the 8 and 12 mg/kg BW group and 2 piglets from the 20 mg/kg BW group following the first or second injection. 
Pri pujskih se je po intramuskularnem dajanju tildipirozina (trikrat v razmikih po 4 dni) v odmerkih 8, 12 in 20 mg/kg telesne teže (2-, 3- in 5-kratni priporočeni klinični odmerek) po prvem ali drugem odmerku pojavilo prehodno rahlo umirjeno vedenje pri enem pujsku v skupinah, ki sta prejemali po 8in 12 mg/kg telesne teže, in pri dveh pujskih iz skupine, ki je prejemala po 20 mg/kg telesne teže.